Delcath Q2 2026 Earnings: Revenue Rises While Clinical Spending Pressures EBITDA

Delcath Systems (Nasdaq: DCTH) reported Q2 2026 revenue of $29.1 million, up about 21% from $24.2 million a year earlier, while diluted EPS was unchanged at $0.07. HEPZATO volume increased approximately 30% and gross margin reached 90%, but higher clinical and commercial spending contributed to a decline in non-GAAP adjusted EBITDA.

Core financial results

HEPZATO KIT remained the main growth driver, while CHEMOSAT also generated higher revenue. Cost of goods sold declined despite the revenue increase, lifting gross profit by 25.5% and expanding the reported gross margin by four percentage points.

Those gains did not translate into higher operating income because operating expenses increased faster than gross profit. Net income was nearly unchanged, while adjusted EBITDA and operating cash flow both declined.

Gross-margin percentages are rounded as reported by the company. Adjusted EBITDA is a non-GAAP measure and excludes items including stock-based compensation, interest income, depreciation and income tax expense.

Product performance and clinical expansion

HEPZATO KIT revenue increased about 20% to $27.1 million from $22.5 million, accounting for most of Delcath’s quarterly revenue. The company reported approximately 30% growth in HEPZATO treatment volume and ended the quarter with 31 active treatment centers. CHEMOSAT revenue in Europe increased to $2.0 million from $1.7 million.

Management attributed the commercial momentum to more HEPZATO procedures, expansion of the treatment-center network and physician adoption. CEO Gerard Michel also said physicians were increasingly using HEPZATO with systemic therapies in metastatic uveal melanoma.

Delcath continued to pursue additional indications. The company dosed the first patient in a global Phase 2 trial evaluating HEPZATO with standard of care in liver-dominant HER2-negative metastatic breast cancer. Independent investigators also presented retrospective breast cancer data showing a 60% hepatic partial response rate in heavily pretreated patients, along with two trials-in-progress involving melanoma combination regimens. These programs remain clinical-development efforts rather than established commercial indications.

Higher clinical and commercial spending offset gross-margin gains

Delcath generated approximately $5.3 million more gross profit than a year earlier, but total operating expenses rose by about $5.5 million. As a result, operating income slipped to $2.4 million even though revenue and gross margin improved.

Research and development expense increased about 51% to $10.4 million, primarily because of additional clinical headcount and trial activity. Selling, general and administrative expense rose about 18% to $13.4 million as the company continued its commercial expansion.

Adjusted EBITDA fell by $2.2 million to $7.6 million. The non-GAAP reconciliation also shows that the stock-based compensation add-back decreased to $5.1 million from $7.2 million. Quarterly operating cash flow remained positive at $5.7 million but was below the prior-year period’s $7.3 million.

Delcath ended June with $95.9 million in cash and investments and no debt. That balance provides financial capacity for clinical and commercial investment, although the relationship between spending growth and future revenue remains an important measure of operating leverage.

2026 guidance

Delcath raised its full-year revenue outlook, although the prior guidance range was not included in the supplied release. The company also expects at least 28% HEPZATO volume growth, a full-year gross margin between 86% and 89%, and positive adjusted EBITDA.

The revenue increase and volume target indicate that treatment-center productivity and physician adoption will remain central to achieving the outlook. Expense control will also be relevant because adjusted EBITDA declined in the quarter despite higher revenue and gross margin.

Risks investors should monitor

• Dependence on HEPZATO: HEPZATO generated $27.1 million of Delcath’s $29.1 million in quarterly revenue. Treatment-center expansion, physician adoption, reimbursement and supply execution therefore have a direct effect on overall performance.
• Clinical and commercial expense growth: R&D and SG&A spending increased materially and absorbed the additional gross profit generated during the quarter. Continued spending growth without corresponding revenue gains could pressure operating income and adjusted EBITDA.
• Cash-flow conversion: Operating cash flow remained positive but declined about 22% year over year while revenue increased. Future quarters will show whether higher commercial activity and clinical spending can produce stronger cash generation.
• Margin sustainability: The Q2 gross margin of 90% was above the company’s full-year guidance range of 86% to 89%, so investors should not assume the quarterly level will persist throughout 2026.
• Execution in additional indications: Breast and colorectal cancer represent potential expansion opportunities, but the programs discussed remain under clinical evaluation and are not established sources of revenue.

Summary

Delcath’s Q2 2026 revenue growth was led by higher HEPZATO volume, while lower product costs supported a wider gross margin. Increased clinical and commercial expenses nevertheless kept net income nearly flat and reduced adjusted EBITDA and operating cash flow. The main items to monitor are progress toward the raised revenue guidance, expense leverage, treatment-center productivity and the development of HEPZATO beyond its current commercial use.